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The evolution of drug resistance threatens human
health worldwide. An emerging strategy to mitigate
drug resistance is combination therapy. The fate
of multidrug-resistant pathogens depends on their
fitness relative to susceptible counterparts, yet the
fitness consequences of multidrug resistance remain
enigmatic. Here, we dissect fitness consequences
of the evolution of resistance to antifungal drug
combinations in the leading human fungal pathogen,
Candida albicans. We focus on the most widely de-
ployed antifungals, the azoles, and inhibitors of the
molecular chaperone Hsp90 and protein phospha-
tase calcineurin, which regulate cellular stress re-
sponses required for azole resistance. We find trade-
offs such that adaptation to drug combinations is
associated with reduced fitness in distinct environ-
ments, including those relevant to the human host.
We identify mutations associated with fitness trade-
offs in clinical isolates and that influence mor-
phogenesis, a key virulence trait. Thus, we delineate
evolutionary constraints that may minimize the evo-
lution of resistance to antifungal combinations.
INTRODUCTION
The evolution of drug resistance is a looming public health
crisis. Imprudent use of antimicrobials in agriculture and med-
icine compromises the effectiveness of our arsenal of drugs, as
the rate at which new antimicrobials are developed does not
keep pace with the rapid emergence of resistance (Laxminar-
ayan et al., 2013). Resistance complicates medical outcomes,
imposes significant financial burdens, and threatens a post-
antibiotic era of medicine (Andersson and Hughes, 2011).
Thus, reducing the spread of drug resistance is of critical
importance.
Drug-resistance mechanisms provide a clear fitness advan-
tage for the pathogen in the presence of drug, but their main-
tenance in the absence of drug selection is contingent on
minimal fitness costs of resistance (Gagneux et al., 2006; Ma-
cLean et al., 2010). Resistance mechanisms often alter key
cellular functions; thus, resistance is frequently associated
with a cost in the absence of drug. Epidemiological modelsCeand experimental evidence suggest that this can slow the
spread of resistance (Andersson and Hughes, 2010), yet
drug resistance is not necessarily costly. For example, an
isochromosome (i5L) in the fungal pathogen Candida albicans
confers resistance to the antifungal azoles and is not delete-
rious in the absence of drug (Selmecki et al., 2009). Under-
standing whether drug resistance is costly in clinically relevant
environments is crucial to evaluating whether resistance will
persist.
Drug-combination therapy is a promising strategy to decrease
the rate of drug resistance. Combination therapy can enhance
the utility of antimicrobials by hindering the evolution of
resistance, such as by targeting cellular processes required for
resistance. An example is to cripple cellular stress response
regulators when treating human pathogens like C. albicans.
C. albicans is the fourth most common cause of hospital-ac-
quired infection, and systemic C. albicans infections are recalci-
trant to treatment, with mortality rates approaching 40% (Pfaller
and Diekema, 2010). The most frequently deployed class of
antifungals is the azoles; however, they are fungistatic and
vulnerable to resistance (Anderson, 2005). Resistance is often
contingent on the molecular chaperone Hsp90, which regulates
key stress response proteins, including the protein phosphatase
calcineurin (Cowen and Lindquist, 2005; Singh et al., 2009).
Combination therapy with an inhibitor of Hsp90 or calcineurin
and an azole provides a powerful strategy for rendering azole-
resistant C. albicans infections responsive to treatment (Cowen,
2009). However, we must anticipate that resistance to drug
combinations will evolve. We recently established an experi-
mental evolution approach to track the evolution of resistance
to drug combinations, and while most lineages went extinct, a
minority was able to evolve resistance to the azole fluconazole
(FL) in combination with the Hsp90 inhibitor geldanamycin
(GdA) or the calcineurin inhibitor FK506. The fitness conse-
quences of the evolution of resistance to drug combinations
remain enigmatic.
Several questions emerge about the fitness consequences
of resistance to drug combinations. Is resistance to drug
combinations costly in the absence of drug or in the presence
of a single drug? Does resistance to these drug combina-
tions, particularly ones that target stress response regulators,
confer cross-resistance to novel stress environments? Or
does resistance to drug combinations create a trade-off in
other environments? To address these questions, we take
advantage of two distinct sets of strains of FL-resistant
C. albicans that evolved resistance to FL and an inhibitor ofll Reports 10, 809–819, February 10, 2015 ª2015 The Authors 809
Figure 1. Lab-Passaged Strains and Late-
Stage Clinical Isolates of C. Albicans
Evolved Resistance to Drug Combinations
(A) Of the seven experimentally evolved strains, six
are resistant to FL and FK506, and one is resistant
to FL and GdA.
(B) A series of clinical isolates recovered over 2
years from a single patient have a two-step in-
crease in resistance to drug combinations. Sub-
sequent analyses focus on key isolates reflecting
the two-step increase in resistance to these drug
combinations (CaCi-2, CaCi-12, CaCi-13, CaCi-
15, CaCi-16, and CaCi-17), indicated by the pink
triangles.
(C and D) Fitness of in vitro (C) and in vivo (D)
evolved strains was assessed relative to their
respective ancestors in FL and GdA (top) and FL
and FK506 (bottom). Generally, in vitro evolved
strains passaged in FL and FK506 (Chr4(2n+1),
Chr4,R(2n+1), Chr4,7(2n+1), Chr4,5R,6,7(2n+1),
LCB1L390F, CNA1S401Stop) are more fit in that
environment but not in FL and GdA and vice versa
(HSP90D91Ywas passaged in FL and GdA). In vivo-
evolved strains increase in fitness in both FL and
GdA and FL and FK506 over time, despite not
having experienced these drug combinations in
the host. Susceptibility assays were performed in
duplicate at 30C for 48 hr, where optical densities
were standardized to no drug control wells.
Data in (C) and (D) are represented as mean ±
SEM. *p < 0.05, **p < 0.01. See also Table S1.Hsp90 or calcineurin in either a human host (in vivo) or a labo-
ratory environment (in vitro). Here, we determine the fitness ef-
fects of resistance to drug combinations in these two sets of
C. albicans lineages and identify mutations associated with
fitness trade-offs in clinical isolates. Resistance to the combi-
nation of azole and an inhibitor of Hsp90 or calcineurin could in
principle evolve by the accumulation of mutations that confer
resistance to each class of drug, as was the case with most
of the experimental evolution lineages. Alternatively, azole-
resistance mechanisms that are independent of the cellular
stress response regulators could evolve, as was the case
with the clinical isolates that evolved resistance in the human
host. Leveraging whole genome sequence data, we identified
alleles that render azole resistance independent of Hsp90
and calcineurin in the clinical isolates: TAC1A736V, UPC2A643V,
and ERG11R467K. For both the in vitro and in vivo evolved
strains, adaptation to these drug combinations was associ-
ated with fitness trade-offs in distinct stress environments
relevant to host conditions, including survival in host immune810 Cell Reports 10, 809–819, February 10, 2015 ª2015 The Authorscells. Additionally, while most strains
that evolved resistance to the drug
combinations retained the capacity to
filament in response to inducing cues,
a key virulence trait, clinical isolates
recovered late during treatment and
harboring the TAC1A736V allele were un-
able to filament in response to Hsp90
inhibitors. This work illuminates evolu-tionary constraints that may forecast reduced vulnerability of
antifungal drug combinations to the evolution of resistance in
pathogen populations.
RESULTS
In Vivo and In Vitro Evolution of Resistance to Drug
Combinations
Resistance to FL in combination with GdA or FK506 was studied
in two sets of strains with distinct genetic backgrounds and
different life histories, providing a broader view of the scope of
fitness consequences that accompany the evolution of resis-
tance to antifungal drug combinations. The first set was lineages
that we previously evolved in FL and an inhibitor of Hsp90 (GdA)
or calcineurin (FK506) (Figure 1A) (Hill et al., 2013). Experimental
evolution was initiated with aC. albicans erg3D/erg3D strain that
is resistant to FL in a manner that depends on Hsp90 and calci-
neurin (Cowen and Lindquist, 2005). Mechanisms of resistance
were subsequently identified in seven lineages, using either a
hypothesis-driven approach or inferences from whole genome
sequencing (Hill et al., 2013). Resistance mechanisms were vali-
dated by allele swap assays. Four of the strains resistant to FL
and FK506 harbor widespread aneuploidy (Chr4,5R,6,7(2n+1),
Chr4,7(2n+1), Chr4(2n+1), Chr4,R(2n+1)), implicated in resis-
tance. The remaining two strains resistant to FL and FK506 ac-
quired a substitution in a sphingolipid biosynthesis regulator
(LCB1L390F) or a premature stop codon in the catalytic subunit
of the drug target itself, calcineurin (CNA1S401Stop). Resistance
to FL and GdA occurred in one strain and was due to mutation
in the drug target gene, HSP90 (HSP90D91Y).
The second set of strains resistant to FL and GdA or FK506
evolved resistance in a human host. Six strains from a series of
C. albicans oral isolates from an HIV-infected individual sampled
over a 2-year period of treatment with FL comprise this set (White
et al., 1997). These isolates are clonally related, representing a
case of in vivo evolution. FL resistance of isolates recovered
early during treatment is abrogated byGdA or FK506 (Figure 1B).
Resistance to FL in combination with GdA or FK506 increases in
isolates recovered later during treatment, despite the patient not
having been exposed to GdA or FK506. The increase in resis-
tance to the drug combinations occurs in two steps, and isolates
reflecting these transitions were selected for subsequent fitness
assays (Figure 1).
Strains with Distinct Genetic Backgrounds Resistant to
Drug Combinations Are More Fit Than Ancestral Strains
in Drug Combinations
The increase in resistance todrugcombinations in experimentally
evolved strains and clinical isolates suggests that they may have
a competitive advantage over their ancestors in these environ-
ments. Indeed, competitive fitness assays of each evolved strain
relative to a marked version of the ancestor revealed that strains
evolved in FL and FK506 are more fit than the ancestor in that
environment, while the strain evolved in FL and GdA has no
advantage in that drug combination (Figure 1C). Similarly, the
strain evolved in FL and GdA is more fit than the ancestor in FL
and GdA, while all but one strain evolved in FL and FK506 are
not (Figure 1C). To a large extent, competitive fitness corre-
sponds to differences in growthmeasured in isolation (FigureS1).
Intriguingly, the clinical isolates evolved a two-step increase in
resistance to FL in combination with GdA or FK506 despite hav-
ing no prior exposure to those inhibitors. This two-step increase
in resistance is reflected in a two-step increase in fitness relative
to the ancestor in either FL andGdA or FL and FK506 (Figure 1D).
The fitness profiles correspond to differences in individual
growth rates (Figure S1).
The Mechanism of Resistance in Late-Stage Clinical
Isolates Is Largely Independent of Hsp90 and
Calcineurin, in Contrast to Most Experimentally Evolved
Strains
Despite not having been exposed to GdA or FK506, late-stage
clinical isolates evolved resistance to these drugs in combination
with FL. One possible explanation is that late-stage isolates ac-
quired a FL resistance mechanism that is independent of both
Hsp90 and calcineurin. To test this, we constructed strains in
the background of the first (CaCi-2) and last (CaCi-17) clinicalCeisolates where the only copy of HSP90 was placed under the
control of a tetracycline-repressible promoter (tetO-HSP90/
hsp90). A low concentration of the tetracycline analog doxycy-
cline abrogated FL resistance of the early clinical isolate, but
only modestly reduced resistance of the late clinical isolate (Fig-
ure 2A), phenocopying the effect of GdA. To determine whether
the late clinical isolate is resistant to FL independent of calci-
neurin, we assayed FL resistance in strains where the catalytic
subunit of calcineurin (CNA1) was deleted in the background of
CaCi-2 and CaCi-17. As with Hsp90 depletion, deletion of calci-
neurin in CaCi-2 abrogated FL resistance while calcineurin dele-
tion in CaCi-17 only modestly reduced resistance (Figure 2B),
phenocopying resistance to FL and FK506 in CaCi-2 and
CaCi-17. These results indicate that resistance to FL is largely
dependent on Hsp90 and calcineurin in the early clinical isolate
but independent from these regulators in the late clinical isolate.
In contrast, deleting CNA1 in the background of most in
vitro evolved strains abrogates resistance to FL (Figure 2C),
indicating that the mechanism of resistance in these strains is
calcineurin dependent. However, deletion of CNA1 in the back-
ground of the strain with LCB1L390F does not abrogate FL resis-
tance, indicating that this resistance mechanism is calcineurin
independent.
TAC1A736V, UPC2A643V, and ERG11R467K Confer Hsp90-
and Calcineurin-Independent Azole Resistance in
Late-Stage Clinical Isolates
In order to identify mutations conferring the two-step increase in
Hsp90- and calcineurin-independent FL resistance, we lever-
aged high-coverage whole-genome sequence for each of the
isolates, which was validated by strong concordance between
Illumina base calls and Sequenom iPlex genotyping assays (per-
sonal communication, D. Thompson and A. Regev, Broad Insti-
tute of MIT and Harvard; see the Supplemental Experimental
Procedures and Table S1). The first small increase in resistance
is accompanied by heterozygous UPC2A643V and homozygous
ERG11R467K (at CaCi-13; see Figure 1 and Table S1); heterozy-
gous TAC1A736V arose coincident with the second, larger in-
crease in resistance (at CaCi-16). Only four nonsynonymous
substitutions occurred in coding regions accompanying the first
increase in resistance, and of those, UPC2A643V (a regulator
of ergosterol biosynthesis genes) and ERG11R467K (the target
of FL) have established roles in azole resistance (Hoot et al.,
2011; Lamb et al., 2000). TAC1A736V (a transcriptional activator
of ABC drug transporters and a known mechanism of azole
resistance; Coste et al., 2007) is the single nonsynonymous sub-
stitution that accompanied the larger increase in resistance to
the drug combinations.
To determine whether these alleles confer Hsp90- and calci-
neurin-independent azole resistance, we replaced the native
UPC2, ERG11, and TAC1 alleles in the first clinical isolate,
CaCi-2, with the mutant alleles and assayed resistance to FL
alone and FL in combination with GdA or FK506 (Figure 3). All
strains were able to grow to a high concentration of FL alone,
as expected. Single copies of ERG11R467K, UPC2A643V, and
TAC1A736V individually had minimal effect on resistance to
FL and GdA and caused a minor increase in resistance to FL
and FK506. However, reconstituting the genotype of the lastll Reports 10, 809–819, February 10, 2015 ª2015 The Authors 811
Figure 2. FL Resistance of Clinical Isolates Is Largely Hsp90 and
Calcineurin Independent, in Contrast to In Vitro-Evolved Strains
(A) Transcriptional repression ofHSP90 abrogates FL resistance of the earliest
clinical isolate, CaCi-2, while only minimally decreasing FL resistance in the
last isolate, CaCi-17.
(B) Rendering calcineurin nonfunctional by deletion of its catalytic subunit,
CNA1, abrogates FL resistance in CaCi-2 but has only a minor effect on FL
resistance in CaCi-17.
(C) Deleting CNA1 in the background of four in vitro-evolved strains abrogates
FL resistance, in contrast to the clinical isolates. Deleting CNA1 in the back-
ground of LCB1L390F does not, however, indicating that FL resistance in this
strain is calcineurin independent. Susceptibility assays performed in duplicate
in YPD at 37C for 48 hr (A and B) or at 30C for 24 hr (C). Optical densities were
standardized to no drug control wells.clinical isolate (CaCi-17) with respect to the alleles of in-
terest (UPC2A643V/UPC2; ERG11R467K/ ERG11R467K; TAC1A736V/
TAC1) in the background of CaCi-2 conferred nearly the
same degree of resistance to FL and GdA or FL and FK506 as812 Cell Reports 10, 809–819, February 10, 2015 ª2015 The Authorsis found in CaCi-17 (Figure 3), suggesting that these alleles
are largely responsible for Hsp90- and calcineurin-independent
azole resistance.
Resistance to FL and GdA or FL and FK506 Is Costly in
Several Host Relevant Environments
While strong selective pressure for resistance is exerted in the
presence of the drug combination, resistance mechanisms
may be costly when selection is alleviated in the absence of
drugs (Andersson and Hughes, 2010). We determined whether
strains resistant to FL and GdA or FL and FK506 had a fitness
disadvantage in the absence of drug (rich medium alone, yeast
extract peptone dextrose [YPD]), by competing them against a
GFP-marked version of the ancestral strain. Frequently, a cost
of resistance to drug combinations was found (Figure 4A). Four
of seven in vitro evolved strains were less fit than the ancestor
in the absence of drug, aswere four of five in vivo evolved strains.
We also tested whether resistance to drug combinations is
costly in the presence of FL alone, which the ancestor is resistant
to. While two in vitro evolved strains were significantly less fit
than the ancestor in FL, one strain was more fit (LCB1L390F),
and the remaining strains were not significantly different from
the ancestor (Figure 4B). In contrast, there is a clear trend of
increasing fitness with each subsequent clinical isolate in the
presence of FL.
While there is generally a cost of resistance to drug combina-
tions in the absence of drug, resistance to drug combinations
may confer cross-resistance to different stressful environments.
Alternatively, drug combination resistance mechanisms may be
costly in stressful environments, unlike the environments the
strains were evolved in (antagonistic pleiotropy). We sought to
identify whether resistance to drug combinations has a fitness
disadvantage in a variety of host relevant, novel stress environ-
ments. Fitness was measured during exposure to cell wall stress
(calcofluor white [CFW]), cell membrane stress (SDS), salt stress
(NaCl), oxidative stress (hydrogen peroxide [H2O2]), and temper-
ature stress (42C; Figures 4C–4G).
In general, the in vitro-evolved strains performedworse than or
equal to the ancestor in novel stressful environments, suggesting
that resistance to FL andGdA or FL and FK506 does not promote
cross-resistance to other environmental stresses (Figure 4). The
strain that often fared the worst had the most aneuploidies
(Chr4,5R,6,7(2n+1)), while the strains with point mutations were
largely no different in fitness from the ancestor (with the excep-
tion of LCB1L390F in CFW). The fitness deficit of evolved strains
was greatest in H2O2, a reactive oxygen species produced by
neutrophils andmacrophages upon ingestion of foreign particles
like invading microbes, suggesting that these strains might not
fare well in the host.
Like the in vitro evolved strains, the later clinical isolates gener-
ally faredworse than or equal to the earliest isolate in the different
stress environments (Figure 4), with heat stress as a notable
exception. While in vitro evolved strains fared worse at high tem-
perature, later clinical isolates showed increased fitness. This
may be due to the selective pressure of febrile temperatures
that accompany infections in the host.
Clustering in vitro-evolved strains indicated that point
mutations in the drug targets CNA1 and HSP90 had little
Figure 3. Together, TAC1A736V, UPC2A643V, and ERG11R467K Confer
Resistance to FL with GdA or FK506
(A–C) TAC1A736V,UPC2A643V, and ERG11R467Kwere placed in the background
of CaCi-2 individually or in combinations that reflect genotypes found in later
clinical isolates concurrent with increases in resistance to drug combinations
(UPC2A643V/UPC2 ERG11R467K/ERG11R467K in CaCi-13; UPC2A643V/UPC2
ERG11R467K/ERG11R467K TAC1A736V/TAC1 in CaCi-17). Resistance to FL was
assessed as a single agent (A) or in combination with GdA (B) or FK506 (C).
Individual mutations confer a modest increase in resistance to FL and FK506,
although no effect on resistance to FL andGdA. Recapitulating the genotype of
the last clinical isolate, CaCi-17, confers resistance to FL and GdA and FL and
FK506 to nearly the same FL concentration as found in CaCi-17. Susceptibility
Cefitness consequence overall and that the two aneuploid strains,
Chr4,5R,6,7(2n+1) and Chr4,R(2n+1), were the least fit (Fig-
ure 4H). Clustering in vivo evolved strains indicated that late
clinical isolates had very similar phenotypes (Figure 4I).
Evolved Lineages Have Reduced Fitness in
Macrophages
The fitness deficit of many evolved strains in H2O2 suggests
that they may be more susceptible to killing by host immune
cells such as macrophages. We tested this directly by quanti-
fying macrophage killing for each evolved and ancestral
strain. J774A.1 macrophages were inoculated with individual
C. albicans ancestral and evolved lineages at anMOI of 1:1. After
1 hr, macrophages were lysed and C. albicans survival was
determined. Lineages that had lower fitness in H2O2 also had
reduced survival in macrophages (Figures 5 and S2). Indeed,
later clinical isolates andmost aneuploid in vitro evolved lineages
had lower survival than their ancestors, suggesting that strains
resistant to antifungal drug combinations would be less fit in a
host than their ancestors. We examined this by performing
competition experiments of the evolved strains relative to a
marked version of the ancestral strains in the host model system
Galleriamellonella. Thesewaxmoth larvae are awell-established
system for the study of fungal pathogenesis (Desalermos et al.,
2012; Fuchs et al., 2010). We observed substantial variation
between larvae, suggesting an early bottleneck during infection
(Figure S2), as has been observed with mouse models of
candidiasis (MacCallum and Odds, 2005). Although many
evolved strains showed a trend toward decreased fitness, only
the in vitro evolved strain LCB1L390F had a significant decrease
in fitness in the invertebrate host model.
Late-Stage Clinical Isolates Are Unable to Filament
in Response to GdA due to TAC1A736V-Regulated Efflux
of GdA
We next examined the ability of evolved lineages to undergo
morphogenesis in response to filament-inducing cues. Under
standard laboratory conditions, C. albicans grows as yeast,
but in response to specific cues, it transitions into a filamentous
form. The ability to transition between these morphologies is
a key C. albicans virulence trait (Gow et al., 2012; Shapiro
et al., 2011), and thus another measure of fitness. Filamentation
can be induced by inhibition of Hsp90, by elevated temperature
of 39C that overwhelms Hsp90 function due to global pro-
tein misfolding, or by exposure to serum at 37C (Shapiro
et al., 2009, 2012). We monitored filamentation of the in vitro
and in vivo evolved lineages in response to these cues.
C. albicans lineages evolved in vitro filamented readily in
response to serum and 39C (Figure 6A). These strains are
hypersensitive to GdA, such that both standard filament-
inducing concentrations (10 mM) and low concentrations
(2.5 mM) impaired survival (Figure S3). Lineages evolved in vivo
were also able to filament in response to serum and 39C.
Intriguingly, while isolates recovered from the patient earlyassays performed in duplicate in YPD at 37C for 48 hr. Optical densities
were standardized to no drug control wells. TAC1* = TAC1A736V; UPC2* =
UPC2A643V; ERG11* = ERG11R467K.
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Figure 4. Resistance to Drug Combinations
Is Costly in the Absence of Drug and in
Different Stressful Environments
(A–G) Fitness relative to the ancestor was
measured for in vitro and in vivo evolved lineages
by competitive fitness assays in (A) the absence of
drug, (B) FL alone, (C) the cell wall stress CFW, (D)
the cell membrane stress SDS, (E) salt stress, (F)
the oxidative stress H2O2, and (G) heat stress.
Each circle represents the mean of three replicate
competition experiments, with standard error
bars. Differences in fitness between strains were
determined by ANOVAs with Bonferroni correc-
tions for multiple comparisons and subsequent
Tukey post hoc tests. Data represented as mean ±
SEM. *p < 0.05, **p < 0.01.
(H and I) Clustering strains evolved in vitro (H) or
in vivo (I) by fitness, standardized to the ancestor.
See also Figure S1.during treatment filamented in response to GdA, the last two
isolates recovered did not (Figure 6B).
There are two alternative explanations for the absence of
filamentation in late-stage clinical isolates: Hsp90 inhibition no
longer induces filamentation in these strains, or GdA does not
inhibit Hsp90 function in these strains. To test whether genetic
reduction of HSP90 levels induces filamentation in these strains,
wemonitored filamentation in response to tetracycline-mediated
transcriptional repression of HSP90 in the earliest and last clin-
ical isolate backgrounds. Transcriptional repression of HSP90
in the first and last clinical isolates was sufficient to induce fila-
mentation (Figure 7A), confirming that Hsp90 represses filamen-
tation in these strains. A possible cause for this inability to
respond to GdA is that it could be effluxed from the cell. Consis-
tent with this possibility, the last two isolates have increased
mRNA levels ofCDR1 andCDR2, ABC transporters that are tran-
scriptionally regulated by TAC1 (Coste et al., 2004; White, 1997).
To determine whether TAC1A736V blocks morphogenesis in
response to GdA, we replaced a native allele of TAC1 with
TAC1A736V in the earliest clinical isolate background. Unlike the
parental strain, the strain expressing TAC1A736V did not filament
in response to GdA (Figure 7B), suggesting that TAC1A736V leads
to the overexpression of pumps sufficient to efflux GdA.
DISCUSSION
Here we illuminate key fitness consequences of the evolution of
resistance to drug combinations in C. albicans lineages that814 Cell Reports 10, 809–819, February 10, 2015 ª2015 The Authorsevolved resistance in vitro or in the human
host. While both sets of strains evolve
resistance from FL alone to FL in combi-
nation with GdA or FK506, they have
very different life histories. One set is
comprised of a series of clinical isolates
recovered from a patient treated with FL
over time, and the other set is experimen-
tally evolved from a strain whose FL resis-
tance is conferred by loss of function of
Erg3, followed by selection with FL incombination with GdA or FK506 (Hill et al., 2013). Strains evolved
in test tubes versus in the human host experience vastly different
environments; passage of C. albicans in a host model has been
associated with 5-fold slower growth and greater phenotypic
and genotypic diversity compared with passage in vitro (Forche
et al., 2009). Despite these differences and the distinct mecha-
nisms of azole resistance (Hill et al., 2013) (Figures 2 and 3), these
strains share several fitness traits.
The first question we sought to address was whether resis-
tance to drug combinations is costly in the absence of drug.
Relative to their FL-resistant progenitors, evolved strains are
generally less fit, with four of seven in vitro evolved strains and
three of five in vivo evolved strains less fit than their ancestor.
This indicates that in the absence of drug, resistance to FL in
combination with GdA or FK506 is more costly than resistance
to FL alone. Consistent with a cost of resistance to these drug
combinations, 40% of transplant recipients suffer from inva-
sive fungal infections; however, the combination of antifungal
treatment and immunosuppressive treatments with calcineurin
inhibitors has not selected for the emergence of resistance to
the drug combination in the host (Blankenship et al., 2005;
Paya, 1993; Reedy et al., 2006). Therefore, we examined specific
fitness costs to the in vitro and in vivo evolved strains under mul-
tiple stress conditions.
Overall, the fitness profile of the clinical isolates is very similar
to that of the in vitro evolved strains: competitive fitness is
increased in evolved strains in FL, FL and GdA, and FL and
FK506, while it is decreased in the alternative stresses SDS,
Figure 5. Evolved Strains Are More Readily Killed by Macrophages
Than the Ancestor
Strains were incubated with J774A.1 macrophages for 1 hr before macro-
phages were lysed and viable C. albicans cells quantified by plating for CFUs.
Differences between strains were determined by ANOVAs with Bonferroni
corrections for multiple comparisons and subsequent Tukey post hoc tests.
Data represented as mean ± SD. *p < 0.05; **p < 0.01.
See also Figure S2.CFW, NaCl, and H2O2 (Figure 4). Furthermore, evolved strains
were generally more susceptible to killing by macrophages
than their ancestors (Figure 5). Thus, adaptation to drug combi-
nations is associated with trade-offs in terms of reduced fitness
in host relevant environments. These fitness costs would reduce
the persistence of resistant pathogens when drug selection is
removed following termination of therapeutic regimens. While
later clinical isolates are generally less fit than their progenitor,
the deficit is not so great that they are eliminated by the host
and their emergence could still be favored under conditions
that select for Hsp90 or calcineurin-independent azole resis-
tance, such as with febrile temperatures. Even if resistance
were costly in the absence of drug, it could still evolve in
response to selection.
One example of a strain with high costs to resistance is CaCi-
13, whichwas the least fit clinical isolate in several environments,
including upon phagocytosis by macrophages (Figures 4 and 5).
This isolate corresponds to the first step increase in resistance to
the drug combination, conferred by a homozygous ERG11muta-
tion and a heterozygous UPC2 mutation, suggesting that these
mutations are costly. However, the fitness cost seen in CaCi-
13 is ameliorated by CaCi-15, which suggests that a compensa-
tory mutation arose between isolates CaCi-13 and CaCi-15 that
reduces the cost of harboring ERG11R467K and UPC2A643K.
Compensatory mutations are well established in bacteria (An-
dersson and Hughes, 2010; Schulz zur Wiesch et al., 2010),
but less well documented in fungi (Singh-Babak et al., 2012).
They can facilitate the spread of resistance alleles through a pop-
ulation by ameliorating the cost of resistance, motivating studies
of the spectrum of compensatory mutations that mitigate the
cost of resistance to drug combinations.
We also observed frequent fitness costs to aneuploidy, which
is an established drug-resistance mechanism. Four of the in vitroCeevolved strains that are resistant to FL and FK506 are aneuploid,
and three of the four strains exhibit fitness defects inmost stress-
ful environments and in the absence of drug (Figure 4). Notably,
the strain Chr4(2n+1), which has an additional copy of the small
chromosome 4 alone, suffers minimal negative fitness conse-
quences. In contrast, the strain with themost aneuploid chromo-
somes, Chr4,5R,6,7(2n+1), which carries an extra copy of nearly
half of its genome, has a fitness disadvantage in almost every
environment tested and often has the greatest magnitude of
cost. This suggests that the burden of replicating extra chromo-
somes is costly in many environments. While aneuploidy in
S. cerevisiae generally reduces growth in rich medium and in
stressful conditions, it can confer a fitness advantage depending
on karyotype and conditions (Pavelka et al., 2010). Aneuploid
Candida isolates are often recovered from patients, indicating
that aneuploidy is maintained in a clinical context (Pola´kova´
et al., 2009; Selmecki et al., 2006). Both inhibition of Hsp90
and treatment with FL can induce aneuploidy (Chen et al.,
2012; Harrison et al., 2014), suggesting that this could be a
prevalent resistance mechanism to treatment with these drug
combinations.
The fitness disadvantage exhibited by most strains in several
novel stress environments indicates resistance to FL and GdA
or FL andFK506 does not confer cross-resistance to these condi-
tions. Altogether, our results indicate that resistance to drug com-
binations results in trade-offs in these novel conditions. This is
consistent with previous findings of trade-offs in novel environ-
ments (Cooper and Lenski, 2000; Lang et al., 2009). High costs
of resistance can drastically diminish the likelihood of it evolving
and being maintained, such as with resistance to the antifungal
amphotericin B (Vincent et al., 2013). However, strains grown in
variable environments can produce ‘‘generalists’’ that thrive in
diverse conditions (New et al., 2014), and given that the human
host is a complex and variable environment, cross-resistance to
host-related environments was a plausible expectation. Under-
standing the relationship between fitness trade-offs measured
in vitro and those that manifest in the human host will require
greater insight into fitness of pathogens in host model systems.
While the fitness profiles of in vitro and in vivo strains are quite
similar, a notable difference is at elevated temperature (Figures 4
and S1). At 42C, the later clinical isolates outcompeted the early
isolate. In contrast, the in vitro-evolved strains were equally or
less fit than the ancestor at 42C. A possible explanation for
this discordance is that in the host fever may provide selective
pressure for growth at higher temperatures. Febrile tempera-
tures destabilize proteins, titrating Hsp90 away from clients to
stabilize these proteins, and allow for high temperature growth.
This reduction in available Hsp90 selects for azole resistance
to evolve toward independence fromHsp90 and its client protein
calcineurin in the clinical isolates. While high temperature pro-
vides selective pressure for azole resistance that is independent
of Hsp90 and calcineurin, which results in resistance to drug
combinations in clinical isolates, the converse is not true: resis-
tance to drug combinations explicitly, as selected for in the
in vitro evolved strains, does not confer resistance to high
temperature.
Resistance to an antifungal in combination with an Hsp90 or
calcineurin inhibitor can arise by the evolution of an antifungalll Reports 10, 809–819, February 10, 2015 ª2015 The Authors 815
Figure 6. Late-Stage Clinical Isolates Do Not Filament in Response to GdA
(A) In vitro evolved strains grow as yeast in 30C, but filament in response to 39C and 10% serum at 37C in YPD after 6 hr.
(B) Clinical isolates grow as yeast in 30C, but filament in response to 39C and 10% serum at 37C. Late-stage isolates are unable to filament in the response to
10 mM GdA at 30C, unlike early-stage isolates. Strains were grown in YPD for 6 hr. Scale bar represents 10 mm.
See also Figure S3.resistance mechanism that does not depend on the cellular
stress responses regulated by Hsp90 or calcineurin, or it can
arise by the evolution of resistance to the inhibitor of Hsp90 or
calcineurin in an antifungal-resistant background. Resistance
of the first clinical isolate is dependent on Hsp90 and calcineurin,
but in the last clinical isolate, resistance is largely independent
of these regulators (Figure 2). In contrast, resistance to drug
combinations in two of three in vitro evolved strains is still depen-
dent on calcineurin. This highlights a difference between strains816 Cell Reports 10, 809–819, February 10, 2015 ª2015 The Authorsevolved with inhibitors of Hsp90 or calcineurin, as opposed to
the selective pressures operating in the human host. The resis-
tance mechanisms that prevail depend on the nature of the
selection pressure, the initial genotype, and the accessibility of
adaptive peaks in the adaptive landscape. Divergent adaptive
trajectories could be favored by low fitness intermediates.
Indeed, there is negative epistasis between an Hsp90-inde-
pendent mechanism of resistance (a hyperactivating mutation
in PDR1, a transcriptional activator of drug pumps) and an
Figure 7. TAC1A736V Abolishes Filamentation in Late-Stage Clinical Isolates
(A) Transcriptional repression of HSP90 in both the first and last clinical isolate induces filamentation. All strains were grown in YPD with a low concentration of
doxycycline (0.03125 mg/ml) for 18 hr at 30C, for transcriptional repression of HSP90 in the tetO- HSP90 strains.
(B) TAC1A736V confers resistance to GdA. After 6 hr in YPD with 10 mM GdA at 30C, CaCi-2 grows filamentously, while CaCi-17 grows as yeast. The ability to
undergo morphogenesis is abolished in CaCi-2 when a WT copy of TAC1 is replaced by TAC1A736V in that background. Scale bar represents 20 mm.Hsp90-dependent mechanism of resistance (loss of function of
Erg3) in S. cerevisiae (Anderson et al., 2003). The extent of epi-
stasis between resistance mechanisms is a fascinating area for
future study.
Within a strain, different traits can also vary in dependence on
Hsp90 and calcineurin. This is illuminated by our findings that
resistance to FL is largely independent of Hsp90 and calcineurin
in late-stage clinical isolates, as opposed to a resulting from
resistance toGdA or FK506. In contrast, morphogenesis remains
under the control of Hsp90 in these strains, such that transcrip-
tional repression of HSP90 induces filamentation despite the
strains being blocked in morphological response to GdA (Fig-
ure 7). While resistance to FL and GdA in the last clinical isolate
is mostly independent from Hsp90, GdA efflux facilitated by
TAC1A736V imparts additional resistance to the drug combination
and is an example of a mechanism of positive cross-resistance
(resistance to more than one drug, here, FL and GdA) (Palmer
and Kishony, 2013).
Drug-combination therapy is emerging as the treatment of
choice for several difficult-to-treat infectious agents. In partic-
ular, targeting fungal stress responses, particularly Hsp90, dras-
tically reduces resistance to the three most commonly deployed
classes of antifungals in C. albicans (Cowen et al., 2009; Singh
et al., 2009; Vincent et al., 2013) and other fungal pathogens
(Cowen, 2013). Determining the mechanisms of resistance to
drug combinations and their fitness effects is crucial to predict-
ing whether these mechanisms will spread in pathogen popula-
tions. Our work demonstrates pervasive fitness trade-offs thatCemay minimize the evolution of resistance to drug combinations
in the human host. An appreciation of the fitness consequences
and evolutionary dynamics of resistance to drug combinations is
crucial in light of the rapid emergence and spread of multidrug
resistance in diverse pathogen populations.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
Strains used in this study are listed in Table S2. The construction of these
strains is described in the Supplemental Experimental Procedures. Strains
are maintained at 80C. To perform experiments, archived strains were
struck out on YPD plates (2% bacto-peptone, 1% yeast extract, 2% glucose,
2%agar), and subsequent overnight cultures were grown in 10ml liquid YPD at
30C.
Plasmid Construction
Standard recombinant DNA techniques were used to create plasmids. Plas-
mids used in this study are listed in Table S3. Primers used in this study are
listed in Table S4. Plasmid construction is detailed in the Supplemental Exper-
imental Procedures.
Drug Susceptibility Assays
Susceptibility to drug combinations was determined using 96-well microtiter
plates, as previously described (Cowen and Lindquist, 2005; Singh et al.,
2009). A gradient of FL (Sequoia Research Products) was initiated at a starting
concentration of 256 mg/ml and diluted 2-fold per well, where the final well con-
tained no FL. When a constant amount of GdA (Invivogen) or FK506 (A. G. Sci-
entific) was present, it was at a concentration of 5 and 12.5 mM, respectively.
FL stock was prepared in ddH2O; GdA and FK506 stocks were prepared in
DMSO. Overnight cultures were diluted to103 cells/ml and used to inoculatell Reports 10, 809–819, February 10, 2015 ª2015 The Authors 817
wells to a final volume of 0.2ml/well. Plates were wrapped in foil and incubated
at the temperature and for the amount of time indicated. Final cell densities
were determined by measuring OD600 using a spectrophotometer (Molecular
Devices). Data were plotted using Java Treeview 1.1.3 (http://jtreeview.
sourceforge.net/). Susceptibility was assessed in duplicate and on multiple
occasions, confirming reproducibility of the data.
In Vitro Competition Experiments
Fitness of each evolved strain was determined relative to a GFP+, nourseothri-
cin (NAT)-resistant version of its ancestor. Freshly struck strains were grown
overnight in isolation in YPD. The next day, cell densities were determined
by counting cells using a hemocytometer. Competition mixes were created
at a ratio of 1:1 ancestor to evolved strain cells (107 cells/ml). Aliquots from
competition mixes (100 ml) were used to inoculate three replicates of 10 ml
fresh medium. Competitors were grown together for 24 hr with constant agita-
tion at 30C, except the competition performed at 42C. Initial and final cell
densities were determined by flow cytometry using Guava EasyCyte (Guava
Technologies, Stanford) and analyzed using FlowJo software (Stanford Uni-
versity). The fitness difference between strains was calculated by subtracting
the natural log of the ratio of the evolved population (final density over initial
density) from the natural log of the ancestral population and then dividing by
the number of generations over which the competition occurred (Travisano
and Lenski, 1996). Concentrations for novel stresses were optimized by first
performing growth curve assays with a series of stressor concentrations
with the ancestor. Competitions were performed at the drug and stressor con-
centrations listed in Table S5.
Macrophage Killing Assay
J774A.1 macrophage cells were washed and then incubated overnight in
RPMI containing 3% fetal bovine serum in 96-well plates at a density of 1 3
105 cells/well. C. albicans strains were grown overnight in individual YPD cul-
tures, washed in PBS, and diluted to 1 3 106 cells/ml in RPMI containing 3%
FBS. The inputC. albicans cultures were plated for colony forming units (CFUs)
to control for cell viability before infection. The adhered J774A.1 macrophages
were infected with C. albicans at an MOI of 1:1. After 1 hr of coinfection, the
macrophages were lysed, and the C. albicans cells were plated for CFUs.
Filamentation Assays
Overnight cultures were diluted to an OD600 of 0.1 in 2ml then subject to one of
the following treatments: 10% fetal bovine serum (Gibco), 2.5 mM or 10 mM
GdA (A. G. Scientific) or 0.03125 mg/ml doxycycline (BD Biosciences), as
described. Imaging was performed with differential interference contrast mi-
croscopy using a Zeiss Axio Imager.MI with Axiovision software (Carl Zeiss).
Cidality Spotting Assay
Viability of cultures after treatment for 6 hr with 2.5 mM or 10 mM GdA was
tested by serially diluting cultures 10-fold five times with PBS then spotting
on to YPD plates. Plates were incubated at 30C for 48 hr then imaged.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.01.009.
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